aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange in the Prime Standard segment, has named Biense Visser, 56, currently a member of aap’s Supervisory Board and CEO of the Dutch company De Ruiter Seeds B.V., as the new chief executive officer of aap Implantate AG. Today, the Supervisory Board appointed him as a member of the Management Board and, with effect from January 1, 2009, as the Board’s chairman. In addition to his work as CEO, Mr. Visser will also be in charge of Finance. Biense Visser is a Dutch citizen, studied pharmacy, holds an MBA and has many years’ experience as a CEO of various pharmaceutical and healthcare companies. In taking up his appointment at aap, Mr. Visser will stand down as Board Chairman of De Ruiter Seeds B.V., Bergschenhoek, The Netherlands.

His place on aap’s Supervisory Board will be taken by Ronald Meersschaert, 46, who was elected as a substitute member of the Supervisory Board at the last Annual General Meeting. Mr. Meersschaert is currently a partner in the private equity company Boekhoorn M. & A. B.V., Arnhem, The Netherlands.

With effect from December 1, 2008, the Supervisory Board named Bruke Seyoum Alemu as Chief Operating Officer. In this function he will be as a member of the Management Board in charge of Development, Production, Sales and Marketing at the aap Group.

Oliver Bielenstein is leaving by mutual agreement as of December 31, 2008, as the company’s CFO and Board member in charge of the medical biomaterials division. Mr. Bielenstein will continue to be at aap’s service as a consultant.

The Management Board and Supervisory Board of aap Implantate AG would like to thank Mr. Bielenstein for his commitment over the past four years and for successfully developing the Group’s biomaterials division.